News Category
VERAXA Biotech's appointment of Raju Willener as CFO brings decades of capital markets expertise as the company advances its BiTAC oncology platform, ...
Apimeds Pharmaceuticals US has hired IBN to enhance corporate communications, aiming to raise investor awareness of its diversified blockchain and bio...
Regentis Biomaterials is advancing its regenerative medicine platform with GelrinC, a treatment for knee cartilage injuries, targeting a large U.S. ma...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property position in developing a novel intranasal treatment for PTSD, add...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, as a potential new treatment for k...
Med-X is expanding its Nature-Cide natural pest control brand as it prepares for a Nasdaq debut, potentially disrupting the conventional pesticide mar...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma models, potentially opening a new translational pa...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS allows the company to initiate a Phase 2 trial in multiple sclerosis, potentially offering a...
GeoVax has entered an agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA, which could help diversify glo...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development to help researchers address stability, targeting, and control...
Creative Biolabs has broadened its single-cell and single-nucleus RNA sequencing and multi-omics services to help researchers overcome sample processi...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering new ta...
GeoVax Labs is appealing a Nasdaq delisting determination while maintaining its strategic focus on advancing its mpox vaccine and cancer immunotherapy...
Regentis Biomaterials reported positive progress in its Phase III GelrinC trial and received European approval for a manufacturing process that boosts...
Quantum BioPharma's FDA clearance to launch a Phase 2 trial of Lucid-MS, a first-in-class myelin-protecting drug, could revolutionize multiple scleros...
TransCode Therapeutics has named John Tattory as interim CFO following Tom Fitzgerald's retirement, bringing extensive financial leadership to support...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer strengthens its scientific leadership as it advances its BiTAC® platfo...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks the first time a drug designed to protect and rebuild myelin will be tested in...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, marking a si...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting and potentially regenerating therapy, receives FDA clearance for a Phase 2 trial, mar...
Helus Pharma's CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, providing a pl...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP and has shown promising preclinical...
Quantum BioPharma's FDA clearance for its Lucid-MS IND allows a phase 2 trial in multiple sclerosis, potentially offering a first-in-class treatment t...
American Fusion has advanced its Texatron fusion program into active testing, achieving peak pressures of 100,000 atmospheres while attracting new res...
Kairos Pharma's CEO presentation at a major investment conference underscores the clinical progress of its lead candidate ENV-105, which aims to rever...
Nutriband's CEO participation underscores the company's strategic positioning in the transdermal pharmaceutical space, leveraging its AVERSA technolog...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores the progress of its intranasal PTSD therapeutic, SPC-15, with stabi...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal step toward a novel therapy that could repair myelin, potentially transfo...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective candidate for multiple sclerosis, has received FDA clearance for a Phase 2 trial and ...
Helus Pharma's CEO participation in the H.C. Wainwright conference highlights the company's progress in developing novel treatments for mental health ...
GeoVax supports the new Gavi-funded global mpox vaccine stockpile, emphasizing the need for diversified supply and highlighting its GEO-MVA candidate'...
Voyageur Pharmaceuticals has achieved the first milestone in its Bayer collaboration, receiving a USD $1 million payment for its iodine extraction fea...
Greenland Mines announces a Q4 biotech spin-off and progresses its rare earth projects, positioning itself as a key supplier of critical minerals to r...
VERAXA Biotech's appointment of seasoned financial leader Raju Willener as CFO signals a strategic move to strengthen its capital position and advance...
Scinai Immunotherapeutics strategically pivots its R&D to prioritize its NanoAb platform and CDMO business following the termination of its PinCell ag...
Onco-Innovations has made significant progress in manufacturing, IND-enabling activities, and financing to advance its lead oncology candidate ONC010 ...
OS Animal Health's participation in the Moody Capital conference underscores its strategic push to secure USDA approval for OST-HER2, a promising immu...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class drug targeting myelin repair, marks a significant step toward addr...
Quantum BioPharma's FDA clearance to test Lucid-MS, a first-in-class remyelinating agent, in a Phase 2 trial marks a pivotal step toward a treatment t...
NanoViricides has registered its Phase II Ebola trial in the DRC, marking a significant step in developing an oral antiviral treatment against Ebola v...
Greenland Mines (GRML) announces a strategic pivot to rare earths and critical minerals, including a biotech spin-off, Nasdaq compliance, and a major ...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of its novel multiple sclerosis drug candidate Lucid-MS, marking a significant s...
Quantum BioPharma's FDA clearance to proceed with a Phase 2 trial of Lucid-MS, a novel demyelination-targeting candidate, marks a pivotal step in MS t...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis, marks a s...
The LGL Group's participation in the Moody Capital Solutions conference underscores its commitment to strategic investments in critical technologies a...
Interlink Electronics announces its participation in the Moody Capital 2026 conference, underscoring its strategic growth in sensors and printed elect...
The 2026 Moody Capital Disruptive Growth & Life Sciences Conference is uniquely positioned to address the converging investment opportunities in life ...
